Meiji Holdings Corrects Supplementary Vaccine Sales Data Without Changing Core Financials

Meiji Holdings Co ( (JP:2269) ) has provided an update.

Meiji Holdings Co., Ltd. has announced partial amendments to the supplementary explanatory data accompanying its consolidated financial results for the fiscal year ended March 31, 2025, and for the first and second quarters of the fiscal year ending March 31, 2026. The corrections relate to the pharmaceutical segment’s sales by main products, including recalculated figures for human vaccine sales, year-on-year change, and full-year plan achievement rates, while confirming that the underlying numerical XBRL data remain unchanged.

The company revised previously disclosed figures for human vaccine sales for the first three quarters of fiscal 2025 from ¥30.1 billion to ¥30.0 billion, adjusting the associated year-on-year growth rate and full-year plan achievement rate slightly downward. By clarifying that the corrections are limited to the supplementary explanatory materials and do not affect the official XBRL financial data, Meiji aims to preserve data accuracy and transparency for investors and other stakeholders relying on its segment performance disclosures.

The most recent analyst rating on (JP:2269) stock is a Buy with a Yen4287.00 price target. To see the full list of analyst forecasts on Meiji Holdings Co stock, see the JP:2269 Stock Forecast page.

More about Meiji Holdings Co

Meiji Holdings Co., Ltd., listed on the Tokyo Stock Exchange Prime Market under code 2269, operates as a diversified Japanese group with significant activities in areas including pharmaceuticals. Its pharmaceutical segment covers products such as human vaccines, contributing to the company’s broader healthcare-related portfolio and presence in both domestic and global markets.

Average Trading Volume: 1,992,773

Technical Sentiment Signal: Buy

Current Market Cap: Yen1054.1B

For a thorough assessment of 2269 stock, go to TipRanks’ Stock Analysis page.